The central vasopressinergic system: examining the opportunities for psychiatric drug development.
about
Sexual differentiation of central vasopressin and vasotocin systems in vertebrates: different mechanisms, similar endpointsNeuropeptides in depression: role of VGFInactivation of the oxytocin and the vasopressin (Avp) 1b receptor genes, but not the Avp 1a receptor gene, differentially impairs the Bruce effect in laboratory mice (Mus musculus)Brain vasopressin is an important regulator of maternal behavior independent of dams' trait anxietySpecies, sex and individual differences in the vasotocin/vasopressin system: relationship to neurochemical signaling in the social behavior neural network.Central CRF neurons are not created equal: phenotypic differences in CRF-containing neurons of the rat paraventricular hypothalamus and the bed nucleus of the stria terminalis.Aggression and anxiety: social context and neurobiological links.Social Monogamy in Nonhuman Primates: Phylogeny, Phenotype, and Physiology.Progestin receptor-mediated reduction of anxiety-like behavior in male ratsA hypomorphic vasopressin allele prevents anxiety-related behavior.Introduction of the human AVPR1A gene substantially alters brain receptor expression patterns and enhances aspects of social behavior in transgenic mice.Neurobiology of sociability.Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour.Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.Clock gene modulates roles of OXTR and AVPR1b genes in prosocialityAzetidinones as vasopressin V1a antagonists.The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.Social attention: a possible early indicator of efficacy in autism clinical trials.Innovative approaches for the development of antidepressant drugs: current and future strategiesProspects for the treatment of depression.The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease.Emerging treatments for major depression.Sexual differentiation of vasopressin innervation of the brain: cell death versus phenotypic differentiation.Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].Presence of a pair-mate regulates the behavioral and physiological effects of opioid manipulation in the monogamous titi monkey (Callicebus cupreus).Maternal aggression in rodents: brain oxytocin and vasopressin mediate pup defence.The therapeutic use of vaptans for the treatment of dilutional hyponatremia.Gonadal steroid hormones and the hypothalamo-pituitary-adrenal axis.Vaptans: A new option in the management of hyponatremia.Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imagingCentral vasopressin V1A receptor blockade impedes hypothalamic-pituitary-adrenal habituation to repeated restraint stress exposure in adult male rats.Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia.The arginine vasopressin V1b receptor gene and prosociality: Mediation role of emotional empathy.Effect of Endogenous Arginine-Vasopressin Arising from the Paraventricular Nucleus on Learning and Memory Functions in Vascular Dementia Model Rats.Neuropeptide S alters anxiety, but not depression-like behaviour in Flinders Sensitive Line rats: a genetic animal model of depression.Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat.A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus-pituitary-adrenal axis more integrally in healthy volunteers.Desmopressin as a pharmacological tool in vasopressinergic hypothalamus-pituitary-adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects.Central vasopressin V1A receptor blockade alters patterns of cellular activation and prevents glucocorticoid habituation to repeated restraint stress exposure.
P2860
Q24546110-B235468B-AB2D-4FA7-A1F2-5243F4EEFC72Q24647788-E7D65EDE-734D-43C6-B0BD-D6145C341F50Q24672244-8BDB48CB-31A9-4CB3-8ECA-44BF3CF19590Q28579336-FD0DFF93-03DD-49CE-ADEA-18423DF3B43EQ30394718-642B11B7-B309-44A3-BCD3-6C2BA06F1125Q30449672-BA3E4676-82CB-494F-BA07-6431A516C3A3Q30481903-04E657D9-EFFE-4CBD-9370-12F43DD74533Q33365726-F7BA64FE-B73A-4871-B728-3FFD12EEE99CQ33380196-5A0A78AD-2F76-4DE3-BD1B-15EEEB12DC2DQ33428525-4E2C2DE2-618B-43B8-9E37-EC595C9EBAD9Q33935654-72968DEB-21E8-4E64-BACD-8BA8871A164AQ34096686-908CDDCE-2D0B-4BAB-8E46-45CACA0D2974Q34225879-B976CCCC-BA2F-466E-B2A3-3D5ABEBD4D71Q34257617-D41B90F0-07C0-4428-94AB-A0C599A1D494Q34332101-5DAED535-3360-490E-931F-3BF5DD5A763FQ34603610-60BFD07A-066B-4AB7-9F7A-0A895CD49D79Q35137091-96691A70-99B1-46D8-B92A-9E335FF1EA41Q35657152-24F55BD9-FE00-4305-B348-21B01DF6EB91Q36217717-DECBEA4B-1331-4609-87BE-99D1DD876B1FQ36401400-03FAFB4B-1592-4E3F-8D68-9A888660EF52Q36472992-64202B44-4078-48B1-BBE6-BB0F2C09E64DQ36570698-36F78C2E-D0D6-438B-A1F3-E59FC7705D9EQ36730674-11ABB1BF-CF3C-452B-AA5E-11FDC18149E4Q36908879-5E70EC5D-370B-4AC2-8B77-DFF2221A692DQ36962261-F2F1F9EF-9B71-4A90-941F-98D820298631Q37266234-0F7EAF18-B3F7-4BDA-9E53-7734FF78197CQ37304220-890BF6E0-3BF3-46A3-82C8-97B28D3CAD2AQ37911141-F9B1AC2F-0FC2-4224-9C8D-FE72B37C9898Q38163719-29D3ACE4-3990-4F15-A5E0-1B1AF8716C57Q39400678-8746CF1A-E33F-4942-9D4C-343E6E32F9A2Q39411491-AA4079C6-1A7F-4095-AEDA-8AAAD242FCD4Q42075574-0E39C549-91FB-4057-9F2C-5A471AE61DD6Q46127896-770E0F61-09C3-4DC7-90BC-1EEF39FD33D6Q47648818-5B3DB663-9B36-4C2F-855A-6C941783B3D3Q47716774-8CADC0CD-1CAF-4E8B-9C8F-DF05FC27E84EQ48127239-C03DBB94-3FCB-477D-85CC-46844A671320Q48233735-03E93093-6949-4966-B056-A45F309AC11BQ48312263-12593826-1C0D-4897-A015-CFB629E1E44AQ48315277-3594339E-B499-455F-BD77-8A205A3B8491Q48723275-81EE35B9-5361-4101-9101-E38C4B82C588
P2860
The central vasopressinergic system: examining the opportunities for psychiatric drug development.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The central vasopressinergic s ...... psychiatric drug development.
@ast
The central vasopressinergic s ...... psychiatric drug development.
@en
type
label
The central vasopressinergic s ...... psychiatric drug development.
@ast
The central vasopressinergic s ...... psychiatric drug development.
@en
prefLabel
The central vasopressinergic s ...... psychiatric drug development.
@ast
The central vasopressinergic s ...... psychiatric drug development.
@en
P356
P1476
The central vasopressinergic s ...... psychiatric drug development.
@en
P304
P356
10.2174/1381612053382241
P577
2005-01-01T00:00:00Z